Progress in lentiviral vector-mediated gene therapy for Alzheimer's disease and Parkinson's disease.

Author: Derun XU ¹ ; Li LIU ² ; Minglin LANG ¹
Author Information

1. CAS Center for Excellence in Biotic Interactions, College of Life Sciences, University of Chinese Academy of Sciences, Beijing 100049, China.
2. State Key Laboratory of Brain and Cognitive Science, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China.
Publication Type:Review
Keywords: Alzheimer’s disease; Parkinson’s disease; gene therapy; lentiviral vector
MeSH: Alzheimer Disease/therapy*; Genetic Therapy; Humans; Parkinson Disease/therapy*
From: Chinese Journal of Biotechnology 2020;36(12):2707-2718
CountryChina
Language:Chinese
Abstract: Alzheimer's disease (AD) and Parkinson's disease (PD) are common neurodegenerative diseases in human. The pathogenesis of AD and PD is complex, and the current drugs and surgical treatments have not successfully alleviated or terminated the progression of the diseases. The lentiviral vector (LV) is a retroviral vector. In recent years, LV mediated gene therapy has been a hotspot to study the mechanisms of human disease and clinical drug discovery. This review summarizes the recent progresses in the treatment of AD and PD by the application of LV, and offers a prospect for its application.